

Fig. 1 PCR-RFLP analyses of the family of Case 6. **a** Strategy (*upper*) and result (*lower*) of PCR-*Sac* II RFLP analysis to detect c.631C > T mutation in *PROC*. Pt: patient, F: father, M: mother. **b** Strategy (*upper*) and result (*lower*) of mismatch PCR-*Eco*N I RFLP analysis to detect c.1268delG mutation in *PROC*. Pt: patient, F: father, M: mother

Acknowledgments We express gratitude to C. Wakamatsu for her excellent technical assistance. This study was supported in part by Grants-in-Aid from the Japanese Ministry of Health, Labour and Welfare (Research on Measures for Intractable Diseases).

References

1. Esmon CT. Protein-C: biochemistry, physiology, and clinical implications. Blood. 1983;62:1155–8.
2. Reitsma PH, Bernardi F, Doig RG, Gandrille S, Greengard JS, Ireland H, et al. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1995;73:876–89.
3. Broekmans AW, Van der Linde IK, Veltkamp JJ, Bertina RM. Prevalence of isolated protein C deficiency in patients with venous thromboembolic disease and in the population. Thromb Haemost. 1983;50:350.
4. Tait RC, Walker ID, Reitsma PH, Islam SI, McCall F, Poort SR, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 1995;73:87–93.
5. Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood. 2008;112:19–27. doi:10.1182/blood-2008-01-077909.
6. Seligsohn U, Berger A, Abend M, Rubin L, Attias D, Zivelin A, et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med. 1984;310:559–62.
7. Nakayama T, Matsushita T, Hidano H, Suzuki C, Hamaguchi M, Kojima T, et al. A case of purpura fulminans is caused by homozygous Δ8857 mutation (protein C-Nagoya) and successfully treated with activated protein C concentrate. Br J Haematol. 2000;110:727–30. doi:10.1046/j.1365-2141.2000.02230.x.
8. Ozlu F, Kyotani M, Taskin E, Ozcan K, Kojima T, Matsushita T, et al. A neonate with homozygous protein C deficiency with a homozygous Arg178Trp mutation. J Pediatr Hematol Oncol. 2008;30:608–11. doi:10.1097/MPH.0b013e318179a15d.
9. Sakata T, Katayama Y, Matsuyama T, Kato H, Miyata T. Prevalence of protein C deficiency in patients with cardiovascular problems in Japan. Thromb Haemost. 1999;81:466–7.
10. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat. 2000;15:7–12. doi:10.1002/(SICI)1098-1004(200001)15:1<7::AID-HUMU4>3.0.CO;2-N.
11. Miyata T, Sakata T, Yasumuro Y, Okamura T, Katsumi A, Saito H, et al. Genetic analysis of protein C deficiency in nineteen Japanese families: five recurrent defects can explain half of the deficiencies. Thromb Res. 1998;92:181–4. doi:10.1016/S0049-3848(98)00131-5.
12. Yamamoto K, Tanimoto M, Emi N, Matsushita T, Takamatsu J, Saito H. Impaired secretion of the elongated mutant of protein C (protein C-Nagoya). Molecular and cellular basis for hereditary protein C deficiency. J Clin Invest. 1992;90:2439–46. doi:10.1172/JCI116135.
13. Reitsma PH, Poort SR, Allaart CF, Briet E, Bertina RM. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. Blood. 1991;78:890–4.
14. Tsukahara A, Yamada T, Takagi A, Murate T, Matsushita T, Saito H, et al. Compound heterozygosity for two novel mutations in a severe factor XI deficiency. Am J Hematol. 2003;73:279–84. doi:10.1002/ajh.10378.
15. Okumura K, Kyotani M, Kawai R, Takagi A, Murate T, Yamamoto K, et al. Recurrent mutations of factor XI gene in Japanese. Int J Hematol. 2006;83:462–3. doi:10.1532/IJH97.06045.

THE JOURNAL OF GENE MEDICINE
J Gene Med 2009; **11**: 1020–1029.
Published online 15 September 2009 in Wiley InterScience (www.interscience.wiley.com) **DOI:** 10.1002/jgm.1391

RESEARCH ARTICLE

Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice

Akira Ishiwata[1†]
Jun Mimuro[1*†]
Hiroaki Mizukami[2]
Yuji Kashiwakura[1]
Katsuhiro Takano[1]
Tsukasa Ohmori[1]
Seiji Madoiwa[1]
Keiya Ozawa[2]
Yoichi Sakata[1*]

[1]*Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical University, School of Medicine, Yakushiji, Shimotsuke, Japan*

[2]*Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical University, School of Medicine, Yakushiji, Shimotsuke, Japan*

*Correspondence to: Jun Mimuro or Yoichi Sakata, Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, 329-0498, Japan.
E-mail: mimuro-j@jichi.ac.jp; yoisaka@jichi.ac.jp

†Both investigators contributed equally and should be considered as senior authors.

Received: 18 December 2008
Revised: 15 July 2009
Accepted: 20 July 2009

Abstract

Background Gene therapy for hemophilia A with adeno-associated virus (AAV) vectors involves difficulties in the efficient expression of factor VIII (FVIII) and in antibody formation against transgene-derived FVIII.

Methods AAV8 vectors carrying the canine B domain deleted FVIII (cFVIII) gene under the control of the ubiquitous β-actin promoter, the liver-specific human $\alpha 1$ anti-trypsin promoter (HAAT) and the liver-specific hepatic control region (HCR) enhancer/human $\alpha 1$ anti-trypsin promoter complex (HCRHAAT) were used for the expression of cFVIII in FVIII deficient (*fviii*$^{-/-}$) mice.

Results Addition of the hepatic control region enhancer element to the HAAT promoter successfully augmented HAAT promoter activity without loss of liver-specificity *in vivo*. Using this enhancer/promoter complex, a high cFVIII transgene expression was achieved, resulting in increased blood cFVIII activities to more than 100% of the normal canine FVIII levels in *fviii*$^{-/-}$ mice at a 1 : 10 lower dose of the AAV8 vector carrying the cFVIII gene driven by the HAAT promoter. Under short-term immunosuppression, neutralizing antibodies against cFVIII developed in only one out of six mice when the HAAT promoter was used for cFVIII expression, whereas all the mice developed neutralizing antibodies against cFVIII when the β-actin promoter was used for cFVIII expression. No neutralizing antibodies against cFVIII developed in *fviii*$^{-/-}$ mice that received the AAV8 vector carrying the cFVIII gene driven by the HCRHAAT enhancer/promoter complex without immunosuppression.

Conclusions These data suggest that AAV8 vector-mediated liver-restricted cFVIII gene expression is sufficient for immune hypo-responsiveness to transgene-derived cFVIII in *fviii*$^{-/-}$ mice. Copyright © 2009 John Wiley & Sons, Ltd.

Keywords adeno-associated virus vector; factor VIII; gene therapy; hemophilia A

Introduction

Hemophilia A is an inherited X-linked bleeding disorder caused by abnormalities in the coagulation factor VIII (FVIII) gene. The genetic

Copyright © 2009 John Wiley & Sons, Ltd.

abnormalities result in FVIII deficiency, which in turn creates bleeding diathesis, such as life-threatening bleeding in the brain or harmful bleeding in joints and muscles. The current standard therapy involves the intravenous injection of monoclonal antibody-purified coagulation factor concentrates from plasma or recombinant coagulation factors. Hemophiliacs are not free from the risks of life-threatening intracranial bleeding and harmful bleeding. Therefore, gene therapy enabling the prevention of such bleeding by a sustained elevation of coagulation factor levels provides the next generation therapy for hemophilia [1–6]. Indeed, clinical trials for hemophilia gene therapy have recently been conducted, although with limited success [4–10]. Compared with gene therapy for hemophilia B, gene therapy for hemophilia A has been accompanied by difficulties involved in the efficient expression of FVIII because of the large size of the FVIII gene and the low expression of the FVIII gene in the full-length FVIII cDNA form. Recent studies have seen the development of new vectors and strategies [11–17]. Among the viral vectors, recombinant adeno-associated virus (AAV) vectors are preferred for gene therapy because they can transfer genes to nondividing cells, leading to the long-term expression of transgenes, and no pathological effects of wild-type AAV have been reported [1–7,11,18]. Because of the size limitation of genes carried on AAV vectors, the use of AAV vectors for hemophilia A gene therapy has not been as successful as that for hemophilia B. Recently, modification of the FVIII gene and the development of new AAV serotype vectors has allowed us to carry the FVIII gene on AAV vectors [15,19,20]. We previously demonstrated that canine B domain-deleted FVIII (BDDFVIII) could be expressed in skeletal muscles and liver using AAV1 vectors and AAV8 vectors, respectively, and the minimum β-actin promoter. In addition to the sustained expression of FVIII, tissue-specific expression of FVIII may also be helpful for hemophilia gene therapy to avoid adverse reactions. In the present study, we examined the possibility of liver-specific FVIII gene transfer in FVIII deficient (*fviii*$^{-/-}$) mice using the AAV serotype 8 vector carrying the canine FVIII (cFVIII) gene, which is located downstream of three different types of promoter/enhancer complex. We show that elevated liver-specific expression of this transgene can be achieved with AAV8 vectors carrying the therapeutic gene under the control of the minimum human α1-antitrypsin (HAAT) promoter in combination with the minimum hepatic control region (HCR) enhancer element *in vivo*. This can be advantageous when aiming to avoid the formation of neutralizing antibodies against the transgene product for long-term expression.

Materials and methods

Vector construction

Two DNA segments encoding the 5′ flanking region (−272 to +25; −168 to +25) of the HAAT gene were amplified by polymerase chain reaction (PCR) to obtain the 297 bp and 193 bp HAAT promoters. These DNA fragments contained the hepatic nuclear factor 1 responsive element. The minimum enhancer element (+24 to +186) of the HCR of the human apolipoprotein E gene [21–23] was also amplified by PCR. DNA fragments of the cytomegalovirus (CMV) promoter and the growth hormone intron 1 of p1.1c (Avigen Inc., Alameda, CA, USA) were replaced with the 297 bp HAAT promoter to generate p1.1HAAT. Similarly, DNA fragments of the CMV promoter and the growth hormone intron 1 of p1.1c were replaced with the minimum HCR enhancer element and the 193 bp HAAT promoter to generate p1.1HCRHAAT. Constructions of p1.1 CAG and p1.1β have been described previously [20,24]. DNA fragments encoding the canine BDDFVIII cDNA or the luciferase gene were placed downstream of the promoter sequences of p1.1HAAT or p1.1 HCRHAAT to produce plasmid vectors p1.1HAAT-cFVIII, p1.1HAAT-Luc, p1.1HCRHAAT-cFVIII and p1.1HCRHAAT-Luc, respectively. Similarly, the DNA fragment encoding the Lac Z gene was placed downstream of the promoter sequences of p1.1 HAAT to produce p1.1HAAT-Lac Z. P1.1β-Lac Z has been described previously [20]. The DNA fragment spanning the CMV promoter, the LacZ gene and the polyadenylation signal sequence of the pAAV2 CMV-Lac Z plasmid (Stratagene, La Jolla, CA, USA) was replaced by the DNA fragment spanning the HCRHAAT promoter, the cFVIII gene and the SV40 polyadenylation signal sequences of p1.1HCRHAAT-cFVIII to make pAAV2-HCRHAAT-cFVIII. Plasmids pAAV2-HCRHAAT-Luc, pAAV2-HAAT-LacZ, pAAV2-CAG-Luc. and pAAV2-HAAT-cFVIII were made in a similar manner, respectively.

AAV vector production

The vector production system was kindly supplied by Avigen Inc. The AAV vectors were packaged with the AAV8 capsid by pseudotyping. The chimeric packaging plasmid for AAV8 capsid pseudotyping was a generous gift from Dr James M. Wilson (Division of Medical Genetics, Department of Medicine, University of Pennsylvania, PA, USA) [19]. The DNA fragments harboring the cFVIII gene, the luciferase gene or the Lac Z gene located downstream of the different promoters and flanked by AAV2 inverted terminal repeats (ITRs) were packaged by triple plasmid transfection of human embryonic kidney 293 (HEK 293) cells, which were kindly supplied by Avigen Inc., with the chimeric packaging plasmid (AAV2 rep/AAV8 cap), the adenovirus helper plasmid pHelper (Stratagene) and gene transfer plasmid vectors, as described previously [20,24]. For virus vector purification, the DNase-treated (Benzonase, Merck Japan, Tokyo, Japan) viral particle containing samples were subjected to two rounds of cesium chloride (CsCl)-density gradient ultracentrifugation in HEPES-buffered saline (pH 7.4) in the presence of 25 mM ethylenediaminetetraacetic acid, at 21 °C, as previously

Copyright © 2009 John Wiley & Sons, Ltd.

DOI: 10.1002/jgm

described [20]. Titration of recombinant AAV vectors was carried out by quantitative dot-blot hybridization using ^{32}P-labeled probes [20,24] or by quantitative PCR using a real time PCR system (StepOnePlus; Applied Biosystems Japan, Tokyo, Japan). The primer sequences used for quantification of the AAV8 vector carrying the cFVIII gene were CCGATTATTGCTCAGTACATCCG and CAACTGTTGAAGTCACAGCCCA, and the probe sequence was FAM-CAACCCATTACAGCATCCGCAGCACT. DNase in the samples was heat-inactivated before the PCR reaction.

Animal experiments

C57BL/6 wild-type mice were purchased from Japan SLC Inc. (Hamamatsu, Japan). FVIII-deficient mice (hemophilia A mice) with targeted destruction of exon 16 of the FVIIII gene were generously provided by Dr H. H. Kazazian Jr (University of Pennsylvania, PA, USA). J1 ES cells were used for targeted destruction of the FVIII gene and blastocysts derived from C57BL/6 mice were used to generate chimaeras [25]. Mice were maintained under standard lighting conditions in a clean room. All surgical procedures were carried out in accordance with the guidelines of the institutional Animal Care and Concern Committee of Jichi Medical University. AAV8 vectors were injected into the cervical vein of mice under anesthesia. Cyclophosphamide (100 μg/body/day; Sigma-Aldrich Japan, Tokyo, Japan) and tacrolimus (12.5 μg/body/day; Fujisawa Pharmaceuticals Co., Tokyo, Japan) were given (subcutaneously) for 12 weeks to AAV8-HAAT-cFVIII-injected $fviii^{-/-}$ mice after vector injection for immunosuppression [20]. No immunosuppresssants were administered to AAV8-HCRHAAT-cFVIII-injected $fviii^{-/-}$ mice.

Immunohistochemistry study

Tissues of vector-injected mice were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 2 h at 4 °C, incubated in PBS containing sucrose (10–30%), and frozen in OCT compound (Tissue-Tek, Miles Inc., Elkhart, IN, USA), in dry ice/ethanol. Sections were prepared from frozen tissues at −25 °C, and attached to polylysine-coated glass slides. For the detection of cFVIII, tissue sections were blocked with 1% casein in PBS containing 0.1% Triton-X 100 for 30 min at room temperature, and incubated with sheep polyclonal anti-human FVIII antibodies (Cedarlane Laboratories Ltd, Burlington, NC, USA) for 2 h at 37 °C. After washing in PBS, sections were incubated with biotin-conjugated rabbit anti-(sheep immunoglobulin G) antibody followed by the ABC reagent and a DAB kit (Vectastain ABC Elite kit; Vector, Burlingame, CA, USA) [20].

Analysis of the Lac Z gene expression in mouse tissues

To analyse LacZ gene expression in mice injected with AAV8 vectors carrying the Lac Z gene, mice were irrigated with saline followed by PBS containing 2% paraformaldehyde and then mouse tissues were fixed in 2% paraformaldehyde in PBS for 5 min and washed with PBS. Portions of mouse tissues were directly suspended in PBS containing 1 mg/ml X-gal, 2 mM $MgCl_2$, 5 mM $K_4Fe(CN)_6$, 5 mM $K_3Fe(CN)_6$, 0.01% Na deoxycholate, 0.1% Triton X-100, at 25 °C for 1 h. The rest of the mouse tissues were incubated further in PBS containing sucrose (10–30%), and frozen in OCT compound (Tissue-Tek) in dry ice/ethanol. Sections were prepared from frozen tissues at −25 °C, attached to polylysine-coated glass slides, incubated in PBS containing 1 mg/ml X-gal, 2 mM $MgCl_2$, 5 mM $K_4Fe(CN)_6$, 5 mM $K_3Fe(CN)_6$, 0.01% Na deoxycholate, 0.1% Triton X-100, at 25 °C for 1 h.

Analysis of luciferase gene expression in mice

For *in vivo* bioluminescence imaging analysis, luciferin (150 μg per 100 μl/g body weight) was given to the mice injected with the AAV8 vector carrying the luciferase gene under anesthesia with isoflurane. Mice were subjected to direct imaging analysis and to quantification of photons transmitted through the mouse skin using IVIS Imaging Systems and Living Image software (Xenogen Co., Alameda, CA, USA). Photons in the area corresponding to the living mouse liver were quantified and expressed as photons/s/cm^2/sr.

Determination of cFVIII and cFVIII gene transcripts in mice

AAV8 vectors carrying the canine FVIII gene driven by the HAAT promoter or the minimum HCRHAAT enhancer/promoter complex were injected into the cervical vein plexus of 8-week-old $fviii^{-/-}$ mice under anesthesia. Blood was drawn from the cervical vein plexus and mixed with 1 : 10 volume of 3.8% sodium citrate periodically. Platelet-poor plasma was prepared and canine FVIII levels in mouse plasma were quantified by the activated partial thromboplastin time (APTT) method using FVIII-deficient plasma and standardized with normal canine plasma. Quantification of cFVIII transgene transcripts was performed by quantitative reverse transcriptase (RT)-PCR. RNA was isolated from mouse organs using an RNeasy Protect isolation kit (Qiagen Inc., Valencia CA, USA). DNase I-treated (Amplification grade; Invitrogen, Carlsbad, CA, USA) and heat-treated RNA samples were subjected to RT-PCR. The quantities of cFVIII transcripts were standardized against those of the GAPDH transcripts [20]. Immunohistochemistry for canine FVIII was carried out

Copyright © 2009 John Wiley & Sons, Ltd.



Figure 1. Schematic representation of AAV8 vectors. AAV8 vectors used in the present study are represented schematically. The promoter, the enhancer/promoter complex, or the enhancer/promoter/intron complexes, the genes for expression, and the polyadenylation signal sequence (pA) were flanked by two AAV2 ITR sequences. CMV, CMV promoter/the growth hormone gene intron 1 complex (1 kb); CAG, the CMV enhancer, β-actin promoter, and growth hormone intron 1 enhancer/promoter/intron 1 complex (1.7 kb); HAAT, the human α1 antitrypsin promoter (297 b); HCRHAAT, the hepatic control region of apolipoprotein E gene (163 b) and the human α1 antitrypsin promoter (193 b) complex; cBDDFVIII, canine B domain deleted FVIII cDNA (4.4 kb).



Figure 2. Lac Z gene expression in mice injected with AVV8 vectors. Expression of the Lac Z gene in vector-injected mice was analysed by X-gal staining. Macroscopic views of organs of mice injected with AAV8-HAAT-Lac Z (a) or with AAV8-CMV-Lac Z (b) and microscopic views of organs of mice injected with AAV8-HAAT-Lac Z (c) or with AAV8-CMV-Lac Z (d) are shown. Arrows indicate positive X-gal staining.

using sheep anti-(human FVIII) polyclonal antibodies, as previously described [20].

Determination of neutralizing antibody titer against cFVIII

Analysis of neutralizing antibodies against cFVIII developed in mice was performed by the Bethesda method using FVIII deficient plasma and normal canine plasma, as previously described [20].

Results

Construction of the AAV vectors

AAV8 vectors used in the present study are represented schematically (Figure 1). The lengths of the AAV8-HAAT-cFVIII and AAV8-HCRHAAT-cFVIII were 5.15 kb and 5.2 kb, respectively. The vector isolation efficiencies of AAV8-HCRHAAT-cFVIII (5.2 kb) and of AAV8-HAAT-cFVIII (5.15 kb) after purification by the two rounds density gradient ultracentrifugation of CsCl were 1.68×10^4 vector genome copies (gc)/cell and 1.87×10^4 vector

Copyright © 2009 John Wiley & Sons, Ltd.

gc/cell (the average of two preparations), respectively, whereas the average vector isolation efficiency of AAV8 vectors carrying the human factor IX gene (4.3 kb) by the same procedure was 3.68×10^4 vector gc/cell (average of three experiments).

Analysis of HAAT promoter specificity with AAV8 vectors *in vivo*

To study the cell specificity of the HAAT promoter *in vivo*, AAV8 vectors carrying the Lac Z gene located downstream of the 297 b HAAT promoter (AAV8-HAAT-Lac Z) or the CMV promoter/growth hormone intron 1 (AAV8-CMV-LacZ) complex were injected into the cervical vein of C57BL/6 mice (5×10^9 gc/g body weight), and expression of the Lac Z gene was analysed by detecting β-galactosidase activity by staining mouse tissues with X-gal. Macroscopic views of organs from mice injected with AAV8-HAAT-Lac Z (Figure 2a) or AAV8-CMV-Lac Z (Figure 2b) and microscopic views of organs from mice injected with AAV8-HAAT-Lac Z (Figure 2c) or AAV8-CMV-Lac Z (Figure 2d) are shown. Arrows indicate positive X-gal staining. The β-galactosidase activity was macroscopically detected in the liver, heart and skeletal muscles of the AAV8-CMV-Lac Z-injected mice (Figure 2), whereas the β-galactosidase activity was solely detected in the liver of the AAV8-HAAT-LacZ-injected mice (Figure 2). These data in respect of β-galactosidase activity expression were confirmed by microscopic examination of these organs (Figure 2). β-galactosidase activities were microscopically detected in hepatocytes, myocardium and skeletal muscle fibers in a similar manner to the macroscopic views of organs of AAV8-CMV-Lac Z-injected mice, whereas no β-galactosidase activities were detected in the myocardium or skeletal muscle fibers in AAV8-HAAT-LacZ-injected mice (Figure 2). These data suggest that the transgene expression with AAV8 vectors preferentially occurs in the liver, but is also affected by the tissue specificity of the promoter used in the AAV8 vector, and that the hepatocyte specificity of the HAAT promoter facilitates liver-restricted transgene expression with the AAV8 vector.

Transgene expression by the HCRHAART enhancer/promoter complex with AAV8 vectors

The DNA fragments spanning the HAAT promoter located downstream of the HCR of apolipoprotein E gene have been shown to express genes in the liver very efficiently [18,26,27]. We could also express human factor IX in mice at approximately 6–7 U/ml (18–21 μg/ml) using the AAV8 vectors carrying the human factor IX gene driven by the HCR enhancer (325 b)/HAAT promoter (297 b) complex (data not shown). However, the DNA fragments used in these studies were too large to enable the FVIII gene to be carried on AAV vectors. Thus, we utilized the minimum HCR enhancer element and the minimum HAAT promoter sequence for FVIII gene expression with AAV8 vectors. Tissue-specific expression of the luciferase gene driven by the HCRHAAT enhancer/promoter complex was quantified by analysing photons from mice under anesthesia using IVIS Imaging Systems (Xenogen Co.) and was compared with that by the CAG promoter. When the AAV8 vectors carrying the luciferase gene driven by the CAG promoter (2×10^9 gc/g) were injected to neonatal wild-type mice, luciferase gene expression was preferentially found in the liver, but also detected in the heart, tail and limbs (Figure 3). By contrast, luciferase gene expression was restricted to the liver in the neonatal mice, with injection of the AAV8 vectors carrying the luciferase gene driven by the minimum HCRHAAT enhancer/promoter complex (2×10^9 gc/g) (Figure 3). When the AAV8 vectors carrying the luciferase gene driven by the CAG promoter were injected into adult mice (2×10^9 gc/g), luciferase gene expression occurred more preferentially in the liver than in neonatal mice, but luciferase gene expression was still observed in the heart and the tail of adult mice. Again, luciferase gene expression was detected solely in the liver of mice injected with the AAV8-HCRHAAT-Luc vector (2×10^9 gc/g). These data suggest that the extrahepatic gene expression with AAV8 vectors may be relatively broad in neonatal mice compared to that in adult mice, and that the HCRHAAT enhancer/promoter complex may have liver specificity not only in adult mice, but also in neonatal mice. In addition, a comparison of the amount of photons from the mouse liver suggests that the minimum HCRHAAT enhancer/promoter complex had approximately ten-fold higher promoter activity than the CAG promoter in the mouse liver *in vivo*.

Expression of FVIII activity in *fviii*$^{-/-}$ mice with AAV vectors carrying the BDD cFVIII gene

FVIII clotting activity levels in hemophilia A mice after intravenous injection of AAV8-HAAT-cFVIII increased dose-dependently on day 28, achieving therapeutic FVIII levels (approximately 0.3 U/ml; 30% of the normal canine FVIII level) and normal FVIII levels in *fviii*$^{-/-}$ mice with the AAV8-HAAT-cFVIII at doses 5×10^9 gc/g and 5×10^{10} gc/g (Figure 4), respectively. FVIII clotting activity levels in *fviii*$^{-/-}$ mice after intravenous injection of AAV8-HCRHAAT-cFVIII were increased dose-dependently on day 28, achieving therapeutic canine FVIII levels (0.32 U/ml) and normal canine FVIII levels (1.45 U/ml) in *fviii*$^{-/-}$ mice with AAV8-HCRHAAT-cFVIII at doses of 5×10^8 gc/g and 5×10^9 gc/g, respectively (Figure 4), indicating that the high cFVIII activity level was achieved with AAV8-HCRHAAT-cFVIII at 1 : 10 of the dose of the AAV8-HAAT-cFVIII and the AAV8-β-actin-cFVIII [20].

Copyright © 2009 John Wiley & Sons, Ltd.

DOI: 10.1002/jgm



Figure 3. *In vivo* **expression of luciferase gene driven by the HCRHAAT enhancer/promoter complex. Wild-type mice injected with AAV8-HCRHAAT-Luc or the AAV8-CAG-Luc on day 1 after birth (a, b) or on day 56 after birth (c, d) were analysed for expression of the luciferase gene using an** *in vivo* **imaging system on day 28 or on day 84, respectively. Photons detected through the mouse skin were visualized (a–d). Significant luminescence was detected at positions corresponding to the liver. Arrows indicate extrahepatic luminescence. No luminescence signal was detected in the nonvector injected mouse (saline, saline-injected mice, control). Photons transmitted through the skin of mice transduced with AAV8-HCRHAAT-Luc or with AAV8-CAG-Luc on day 1 (open square) or on day 56 (closed square) after birth were quantified 28 days after vector injection (e).**



Figure 4. Expression of canine FVIII in ***fviii***$^{-/-}$ **mice injected with AAV8 vectors carrying the canine FVIII gene. The canine FVIII levels in** ***fviii***$^{-/-}$ **mice injected with 5 x 10**^{10} **gc/g body weight of AAV8-HAAT-cFVIII (a) or 5 x 10**^{9} **gc/g body weight of AAV8-HCRHAAT-cFVIII (b) are shown. Values represent the mean ± SD. The canine FVIII levels in** ***fviii***$^{-/-}$ **mice injected with AAV8-HCRHAAT-cFVIII (black bars; doses of 5 x 10**^{8} **gc/g body weight or 5 x 10**^{9} **gc/g body weight) or AAV8-HAAT-cFVIII (white bars; doses of 5 x 10**^{9} **gc/g body weight or 5 x 10**^{10} **gc/g body weight) on day 28 after vector injection are shown (c). FVIII activities were determined by the one-step APTT method using FVIII deficient human plasma and were standardized with normal canine plasma. One unit canine FVIII/ml represents 100% canine FVIII clotting activity.**

Analysis of transcripts of canine FVIII transgene in organs of *fviii*$^{-/-}$ mice injected with AAV8 vectors carrying the canine FVIII gene

Analysis of cFVIII transcripts in vector-injected mice suggests that the cFVIII gene was specifically expressed in the liver (Figure 5) and no significant amount of cFVIII transcripts were detected by RT-PCR or quantitative RT-PCR in other organs of mice injected with AAV8-HCRHAAT-cFVIII or AAV8-HAAT-cFVIII. These data confirm that the expression of the cFVIII gene by the HAAT promoter or the HCRHAAT enhancer/promoter complex was liver specific. Transcript levels of the cFVIII transgene in the liver of AAV8-HCRHAAT-cFVIII injected mice were approximately ten-fold higher than in AAV8-HAAT-cFVIII-injected mice at the same vector dose. These data are in accordance with the cFVIII levels in the vector-injected

Copyright © 2009 John Wiley & Sons, Ltd.

DOI: 10.1002/jgm

mice, suggesting that the HCRHAAT enhancer/promoter complex had ten-fold higher transgene expression activity than the HAAT promoter *in vivo*.

Immunohistochemistry of canine FVIII in the liver of mice injected with AAV8 vectors carrying the canine FVIII gene

Immunohistochemistry analysis confirmed that cFVIII was efficiently expressed in hepatocytes of mice injected with a low dose of AAV8 vectors carrying the cFVIII gene under the control of the HAAT promoter or the HCRHAAT enhancer/promoter complex (Figure 6).

Analysis of anti-cFVIII neutralizing antibody in *fviii*$^{-/-}$ mice

In our previous study, we showed that the expression of the cFVIII gene with the AAV8 vector has an advantage over AAV1 vector-mediated cFVIII gene transfer to the skeletal muscles in terms of the immune reaction to the transgene product [20]. No neutralizing antibody development was observed until 12 weeks after vector injection of AAV8-β-actin-cFVIII under immunosuppression [20]. However, neutralizing antibodies against cFVIII developed in four out of four mice at 12 weeks after termination of immunosuppression (i.e. week 24 after vector injection). When no immunosuppressants were given throughout the course, antibodies against cFVIII were formed in six of eight mice 4–20 (mean 12.8) weeks after AAV8-β-actin-cFVIII vector injection (Table 1). By contrast to the AAV8-β-actin-cFVIII-injected *fviii*$^{-/-}$ mice, neutralizing antibodies were found in only one out of six mice with AAV8-HAAT-cFVIII injection under the same immunosuppression. Interestingly, the level of neutralizing antibody against cFVIII in that mouse gradually decreased and became undetectable by week 8 after termination of immunosuppression (i.e. week 20 after vector injection), and the cFVIII activity in the mouse started to increase from week 12 after termination of immunosuppression (i.e. week 24 after vector injection) and reached a plateau of 0.45 U/ml (45% of the normal canine FVIII level) by week 24 after termination of immunosuppression. Therapeutic levels of cFVIII in other AAV8-HAAT-cFVIII-injected *fviii*$^{-/-}$ mice were sustained for more than 40 weeks without immunosuppression (i.e. week 52 after vector injection) (Figure 4 and Table 1). These data lead us to speculate that the extrahepatic expression of cFVIII gene might correlate with the development of neutralizing antibodies. On the basis of this notion, the AAV8-HCRHAAT-cFVIII vector was injected to *fviii*$^{-/-}$ mice without any immunosuppression and cFVIII expression and neutralizing antibody formation was investigated. High cFVIII gene expression and an elevation of blood cFVIII levels (Figures 4 and 5) without neutralizing antibody formation were achieved in AAV8-HCRHAAT-cFVIII-injected *fviii*$^{-/-}$ mice (Table 1). These data suggest that liver-restricted expression of cFVIII with AAV8 vector and the liver-specific promoter facilitates the prevention of inhibitor formation to cFVIII in *fviii*$^{-/-}$ mice. Although the liver-restricted cFVIII gene transfer facilitated hypo-responsiveness to transgene-derived cFVIII, antibody formation against AAV8 capsid developed in the mice with AAV8-HCRHAAT-cFVIII injection in a similar manner to that in mice receiving other AAV8 vectors (data not shown).



Figure 5. Analysis of transcripts of the canine FVIII transgene in organs of mice injected with AAV8 vectors carrying the canine FVIII gene. The transcripts of canine FVIII transgene in organs of fviii$^{-/-}$ mice injected with 5 x 10^{9} gc/g body weight AAV8-HAAT-cFVIII (a) or 5 x 10^{9} gc/g body weight AAV8-HCRHAAT-cFVIII (b) were detected by RT-PCR and were quantified using real-time PCR. The quantity of canine FVIII transgene transcripts was standardized with GAPDH transcripts (c) (AAV8-HAAT-cFVIII, white bar; AAV8-HCRHAAT-cFVIII, black bar).

Discussion

Various serotypes of AAV vectors have been developed, and each AAV serotype has its own tropism [11]. However, the tropism of an AAV serotype is not completely specific for a certain type of cell and transgene expression in target cells and organs may also be affected by the tissue specificity of the promoter used in the AAV vectors. Ubiquitous promoters, such as the CMV promoter and the CAG promoter, have been used in early studies of gene therapy; however, the use of a tissue-specific promoter for

Copyright © 2009 John Wiley & Sons, Ltd.

DOI: 10.1002/jgm

Figure 6. Immunohistochemistry of canine FVIII in the liver of mice injected with AAV8 vectors carrying the canine FVIII gene. Canine FVIII in the liver of *fviii*$^{-/-}$ mice injected with 5×10^9 gc/g body weight of AAV8-HAAT-cFVIII or 5×10^8 gc/g body weight AAV8-HCRHAAT-cFVIII was detected by immunohistochemistry with sheep anti-human FVIII polyclonal antibodies, as described in the Materials and methods. Positive staining is brown. As a control, liver sections obtained from *fviii*$^{-/-}$ mice without vector injection were simultaneously processed with the same antibody solution as the control.

Table 1. Neutralizing antibody against cFVIII in vector injected *fviii*$^{-/-}$ mice

Vector	AAV8-β-cFVIII	AAV8-β-cFVIII	AAV8-HAAT-cFVIII	AAV8-HCRHAAT-cFVIII
Immunosuppression*	Yes, 12 weeks	No	Yes, 12 weeks	No
CFVIII activity on day 56 after vector injection (%)	77.6 ± 21.3 (mean ± SD)	79.8 ± 81.8 (mean ± SD)	87.5 ± 30.6 (mean ± SD)	127.0 ± 17.1 (mean ± SD)
Neutralizing antibody formation (*n*)	4/4	6/8	1/6	0/6
Inhibitor titer (Bethesda U/ml)	10.7 ± 0.5 (mean ± SD)	18.5 ± 13.6 (mean ± SD)	4.0	Not detected
Spontaneous regression of neutralizing antibody	No	No	Yes	Not applicable

*Cyclophosphamide and tacrolimus were injected to mice after vector injection for 12 weeks.

cell-specific expression of a transgene is required to avoid undesirable effects. One such side-effect is the formation of antibody against the transgene product. In particular, a serious concern in hemophilia A gene therapy is the formation of antibody against transgene-derived FVIII. Liver-specific expression of transgene products upon gene transfer is attractive with regard to immune tolerance induction to the transgene products [18,28–30]. Indeed, AAV vector-mediated gene transfer to the liver has been shown to have a reduced pro-inflammatory risk compared to lentivirus vector-medicated gene transfer [18,31]. In addition, AAV8 vectors and AAV9 vectors do not express transgenes in the spleen [18]. On the basis of these notions, we developed an AAV8 vector carrying the cFVIII gene driven by the HAAT promoter or the HCRHAAT enhancer/promoter complex, and investigated the expression of cFVIII in *fviii*$^{-/-}$ mice.

Canine FVIII is a xenoantigen to mice; therefore, mice might develop neutralizing antibodies to cFVIII if cFVIII is expressed in mice. Indeed, *fviii*$^{-/-}$ mice developed neutralizing antibodies against cFVIII, even under immunosuppression, when the cFVIII gene driven by the β-actin promoter was expressed in skeletal muscles using the AAV1 vector [20]. However, when the cFVIII gene, driven by the same promoter, was transduced to *fviii*$^{-/-}$ mice using the AAV8 vector, no neutralizing antibodies against cFVIII developed in vector-injected *fviii*$^{-/-}$ mice under the same immunosuppression, suggesting that AAV8 vector-mediated FVIII gene transfer to the liver was advantageous over AAV1 vector-mediated gene transfer to the skeletal muscle in terms of neutralizing antibody formation against the transgene product cFVIII. However, the AAV8 vector-mediated cFVIII gene transfer with the β-actin promoter was not sufficient to prevent neutralizing antibody formation against transgene-derived cFVIII, as shown in the present study (Table 1). The present study demonstrated that extrahepatic expression of the transgene might function to develop neutralizing antibodies to cFVIII in *fviii*$^{-/-}$ mice. The minimum β-actin promoter, a part of the CAG promoter, had a significant promoter activity in HEK293 cells and was approximately one-half to one-third of that of the CAG promoter [20]. By contrast, the activities of the HAAT promoter and the HCRHAAT enhancer/promoter complex used in the present study were almost the same as the promoter-less control vector in HEK293 cells (not shown), suggesting that leaky gene expression of the HAAT promoter and the HCRHAAT enhancer/promoter complex in nonhepatocyte cells can be minimized. In addition, the leaky expression of the Lac Z gene driven by the HAAT promoter or of the luciferase gene driven by the HCR/HAAT promoter was not apparent *in vivo* (Figures 2 and 3). On the basis of this notion, we attempted to express cFVIII with AAV8-HCRHAAT-cFVIII in *fviii*$^{-/-}$ mice without immunosuppression to determine whether liver-restricted expression of cFVIII is sufficient for hypo-responsiveness of inhibitor (antibody) formation to cFVIII. In this experiment, none of the mice injected with the AAV8-HCRHAAT-cFVIII developed neutralizing antibodies against canine FVIII for up to 10 months without immunosuppression. Taken together, these data suggest that the liver-restricted transgene expression would be effective to reduce the immune reaction to transgene-derived canine FVIII. Immune tolerance induction to the transgene product is one of the key issues of gene therapy for genetic disease caused by a

Copyright © 2009 John Wiley & Sons, Ltd.

DOI: 10.1002/jgm

single gene abnormality and has been extensively studied in a mouse hemophilia B model by expressing factor IX with viral vectors [18,28–30]. Hypo-responsiveness to transgene product FVIII including immune tolerance induction may be more important for hemophilia A gene therapy than for hemophilia B gene therapy because approximately 21–32% of severe hemophilia A patients develop inhibitors (alloantibody) against therapeutically injected FVIII, whereas inhibitors against factor IX form in approximately 9% of severe hemophilia B patients upon factor IX infusion. A variety of approaches for induction of hypo-responsiveness to FVIII including immune tolerance have been shown to be effective [32–34]. In this regard, liver-restricted expression of FVIII using the AAV8 vector together with the liver-specific promoter might be an alternative gene transfer approach for this purpose.

The vector doses required for the increase of the cFVIII activity level to 0.4–1.2 U/ml in *fviii*$^{-/-}$ mice suggested that the AAV8-HCRHAAT-cFVIII vector was approximately ten-fold more potent than both the AAV8-HAAT-cFVIII and the AAV8-β-actin-cFVIII vectors. Expression of the transgene may be mainly driven by the internal promoter used in the AAV vector; however, it is still possible that transgene expression is affected by the presence of the ITR and the A/D sequences because these elements may function as cis-acting elements in human cells, thereby interfering with the regulated downstream gene expression cassette [35,36]. In the context of minimizing nonspecific transgene expression with AAV vectors, a reduction of vector doses for gene transfer is also important and can be achieved using the AAV8 vector carrying the therapeutic gene driven by the HCRHAAT enhancer/promoter complex to avoid an undesirable immune reaction to the transgene product. This efficient cFVIII expression in FVIII deficient mice could be achieved by the use of this enhancer promoter complex [21,22,27], the removal of the DNA segment coding the FVIII B domain from the FVIII gene [37,38], and the high liver transduction efficiency of the AAV8 vector [11,15,39].

The site of extrahepatic expression of canine FVIII contributing to inhibitor formation has not been determined. One possibility is the expression of FVIII in skeletal muscles [40]. This remains the subject of future studies.

Acknowledgements

This study was supported by Grants-in-Aid for Scientific Research (20591155, 21591249 and 21790920) and Support Program for Strategic Research Infrastructure from the Japanese Ministry of Education and Science, and Health Labour and Science Research Grants for Research on HIV/AIDS and Research on Intractable Diseases from the Japanese Ministry of Health, Labour and Welfare.

References

1. Mannucci PM, Tuddenham EG. The hemophilias – from royal genes to gene therapy. *N Engl J Med* 2001; **344**: 1773–1779.
2. Pasi KJ. Gene therapy for haemophilia. *Br J Haematol* 2001; **115**: 744–757.
3. VandenDriessche T, Collen D, Chuah MK. Gene therapy for the hemophilias. *J Thromb Haemost* 2003; **1**: 1550–1558.
4. Chuah MK, Collen D, Vandendriessche T. Preclinical and clinical gene therapy for haemophilia. *Haemophilia* 2004; **10**(Suppl4): 119–125.
5. Chuah MK, Collen D, VandenDriessche T. Clinical gene transfer studies for hemophilia A. *Semin Thromb Hemost* 2004; **30**: 249–256.
6. Hasbrouck NC, High KA. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects. *Gene Ther* 2008; **15**: 870–875.
7. Kay MA, Manno CS, Ragni MV, *et al.* Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. *Nat Genet* 2000; **24**: 257–261.
8. Jiang H, Pierce GF, Ozelo MC, *et al.* Evidence of multi year factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. *Mol Ther* 2006; **14**: 452–455.
9. Manno CS, Chew AJ, Hutchison S, *et al.* AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. *Blood* 2003; **101**: 2963–2972.
10. Manno CS, Pierce GF, Arruda VR, *et al.* Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. *Nat Med* 2006; **12**: 342–347.
11. Lu Y. Recombinant adeno-associated virus as delivery vector for gene therapy – a review. *Stem Cells Dev* 2004; **13**: 133–145.
12. Chao H, Mansfield SG, Bartel RC, *et al.* Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. *Nat Med* 2003; **9**: 1015–1019.
13. Nakai H, Yant SR, Storm TA, *et al.* Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. *J Virol* 2001; **75**: 6969–6976.
14. Kumaran V, Benten D, Follenzi A, *et al.* Transplantation of endothelial cells corrects the phenotype in hemophilia A mice. *J Thromb Haemost* 2005; **3**: 2022–2031.
15. Sarkar R, Mucci M, Addya S, *et al.* Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. *Hum Gene Ther* 2006; **17**: 427–439.
16. Gnatenko DV, Wu Y, Jesty J, *et al.* Expression of therapeutic levels of factor VIII in hemophilia A mice using a novel adeno/adeno-associated hybrid virus. *Thromb Haemost* 2004; **92**: 317–327.
17. Ohmori T, Mimuro J, Takano K, *et al.* Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ibalpha promoter: in vivo model for platelet-targeting gene therapy. *FASEB J* 2006; **20**: 1522–1524.
18. Vandendriessche T, Thorrez L, Acosta-Sanchez A, *et al.* Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. *J Thromb Haemost* 2007; **5**: 16–24.
19. Sarkar R, Tetreault R, Gao G, *et al.* Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. *Blood* 2004; **103**: 1253–1260.
20. Ishiwata A, Mimuro J, Kashiwakura Y, *et al.* Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene. *Thromb Res* 2006; **118**: 627–635.
21. Simonet WS, Bucay N, Lauer SJ, *et al.* A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. *J Biol Chem* 1993; **268**: 8221–8229.
22. Dang Q, Walker D, Taylor S, *et al.* Structure of the hepatic control region of the human apolipoprotein E/C-I gene locus. *J Biol Chem* 1995; **270**: 22577–22585.
23. Allan CM, Taylor S, Taylor JM. Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/C-II gene cluster. *J Biol Chem* 1997; **272**: 29113–29119.
24. Mimuro J, Muramatsu S, Hakamada Y, *et al.* Recombinant adeno-associated virus vector-transduced vascular endothelial cells express the thrombomodulin transgene under the regulation of enhanced plasminogen activator inhibitor-1 promoter. *Gene Ther* 2001; **8**: 1690–1697.

Copyright © 2009 John Wiley & Sons, Ltd.

25. Bi L, Lawler AM, Antonarakis SE, *et al.* Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. *Nat Genet* 1995; **10**: 119–121.
26. Mount JD, Herzog RW, Tillson DM, *et al.* Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. *Blood* 2002; **99**: 2670–2676.
27. Miao CH, Ohashi K, Patijn GA, *et al.* Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. *Mol Ther* 2000; **1**: 522–532.
28. Cao O, Dobrzynski E, Wang L, *et al.* Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. *Blood* 2007; **110**: 1132–1140.
29. Dobrzynski E, Mingozzi F, Liu YL, *et al.* Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. *Blood* 2004; **104**: 969–977.
30. Mingozzi F, Liu YL, Dobrzynski E, *et al.* Induction of immune tolerance to coagulation factor IX antigen by *in vivo* hepatic gene transfer. *J Clin Invest* 2003; **111**: 1347–1356.
31. Brown BD, Sitia G, Annoni A, *et al.* In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. *Blood* 2007; **109**: 2797–2805.
32. Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40–CD40L interaction in a mouse model of hemophilia A. *Blood* 2001; **97**: 2750–2757.
33. Madoiwa S, Yamauchi T, Hakamata Y, *et al.* Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A. *J Thromb Haemost* 2004; **2**: 754–762.
34. Lei TC, Scott DW. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. *Blood* 2005; **105**: 4865–4870.
35. Flotte TR, Afione SA, Solow R, *et al.* Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. *J Biol Chem* 1993; **268**: 3781–3790.
36. Haberman RP, McCown TJ, Samulski RJ. Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. *J Virol* 2000; **74**: 8732–8739.
37. Miao HZ, Sirachainan N, Palmer L, *et al.* Bioengineering of coagulation factor VIII for improved secretion. *Blood* 2004; **103**: 3412–3419.
38. Dooriss KL, Denning G, Gangadharan B, *et al.* Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A. *Hum Gene Ther* 2009; **20**: 465–478.
39. Nakai H, Fuess S, Storm TA, *et al.* Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. *J Virol* 2005; **79**: 214–224.
40. Cao B, Bruder J, Kovesdi I, *et al.* Muscle stem cells can act as antigen-presenting cells: implication for gene therapy. *Gene Ther* 2004; **11**: 1321–1330.

Copyright © 2009 John Wiley & Sons, Ltd.

DOI: 10.1002/jgm

Journal of Thrombosis and Haemostasis, **7**: 811–824 DOI: 10.1111/j.1538-7836.2009.03314.x

ORIGINAL ARTICLE

Induction of factor VIII-specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A

S. MADOIWA,* T. YAMAUCHI,*† E. KOBAYASHI,‡ Y. HAKAMATA,‡ M. DOKAI,* N. MAKINO,* Y. KASHIWAKURA,* A. ISHIWATA,* T. OHMORI,* J. MIMURO* and Y. SAKATA*

**Research Divisions of Cell and Molecular Medicine, Centre for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi; †Department of Paediatrics, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi; and ‡Research Divisions of Organ Replacement Research, Centre for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan*

To cite this article: Madoiwa S, Yamauchi T, Kobayashi E, Hakamata Y, Dokai M, Makino N, Kashiwakura Y, Ishiwata A, Ohmori T, Mimuro J, Sakata Y. Induction of factor VIII-specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A. *J Thromb Haemost* 2009; **7**: 811–24.

Summary. *Background:* Hemophilia A is a congenital bleeding disorder caused by a deficiency of coagulation factor VIII. Approximately 30% of hemophilia A patients develop inhibitors against FVIII following replacement therapy. We have reported that neonatal exposure of FVIII antigen can induce antigen-specific immune tolerance by interferon-γ (IFN-γ)-dependent T-cell anergy in hemophilia A mice. *Objective:* The thymus plays crucial roles in self-tolerance, with negative selection of self-reactive effector T cells and positive selection of self-reactive regulatory T cells. We investigated the possibility of the induction of antigen-specific immune tolerance by intrathymic injection of FVIII in hemophilia A mice. *Methods:* Hemophilia A mice were injected with recombinant FVIII into the thymus under real-time high-resolution image guidance. *Results:* Anti-FVIII inhibitory antibody titers in mice challenged with intravenous administration of FVIII were significantly lower in mice ($n = 22$) that had received thymic FVIII injection than in mice ($n = 18$) without thymic injection (9.4 ± 2.3 vs. 122.5 ± 27.6 BU mL^{-1}, respectively, $P = 0.00078$). The $CD4^+$ T cells from thymic-injected mice could not proliferate or produce interleukin (IL)-2, IL-12 and IFN-γ in response to FVIII. The $CD4^+CD25^+$ T cells generated from thymic-treated mice but not from naïve mice efficiently suppressed the *in vitro* proliferative response of $CD4^+$ T cells and blocked the *in vivo* development of anti-FVIII antibodies in the adoptive transfer. *Conclusion:* These data suggest that intrathymic administration of FVIII could result in immune tolerance by induction of FVIII-specific regulatory T cells.

Correspondence: Seiji Madoiwa, Research Division of Cell and Molecular Medicine, Centre for Molecular Medicine, Jichi Medical University, 3311-1 Yakushi-ji, Shimotsuke, Tochigi 329-0498, Japan.
Tel.: +81 285 58 7398; fax: +81 285 44 7817.
E-mail: madochan@jichi.ac.jp

Received 24 May 2008, accepted 4 February 2009

© 2009 International Society on Thrombosis and Haemostasis

Keywords: FVIII deficient mice, hemophilia, inhibitor, regulatory T cells, thymic tolerance.

Introduction

Hemophilia A is an X-linked hereditary bleeding disorder caused by deficiency in coagulation factor VIII [1]. Plasma-derived or recombinant FVIII is sufficiently available to permit its use for primary prophylaxis to avoid bleeding in patients with severe hemophilia A. A major complication of hemophilia A treatment is the development of neutralizing antibodies against the infused FVIII [2]. We have previously demonstrated that exposure to FVIII antigen within 24 h of birth induces antigen-specific immune tolerance by interferon (IFN)-γ-dependent T-cell anergy in hemophilia A mice [3].

The thymus plays a major role not only in the development of self-tolerance but also in acquired tolerance in autoimmunity and organ transplantation [4,5]. There are two mechanisms in the thymus to establish a self-tolerance system, consisting of negative selection of self-reactive effector T cells, and positive selection of self-regulatory $CD4^+CD25^+$ T cells [6,7,4,8]. The $CD4^+CD25^+$ T cells are known to be weakly reactive to antigenic stimulation and able to mediate suppression of $CD25^-$ naïve T cells [9,10]. In the thymus, $CD4^+CD25^+$ T cells are detected during the fetal period in humans, and during the perinatal period in mice [11]. The $CD4^+CD25^+$ T cells may be responsible for the translation of tolerance from an antigen-inoculated thymus to a mature but naïve peripheral immune system [12] [13]. Injection into the thymus of organs or cells has been successful in the induction of T-cell-mediated immunologic tolerance [14,15,16]. Allogenic grafts of pancreatic islets had better survival when grafted in the thymus, and provided long-term protection against spontaneous autoimmune diabetes if grafted during the early period after birth [17]. The expression or presentation of nominal antigen in the thymus might lead to enhanced deletion of autoreactive T cells or to induction of a number of antigen-specific regulatory T cells. In this study, we investigated the possibility of the

induction of antigen-specific immune tolerance by intrathymic injection of FVIII in hemophilia A mice. Our study may open new perspectives for the manipulation of FVIII-specific tolerance in the thymus of hemophilia A patients.

Materials and methods

Hemophilia A mice

FVIII-deficient mice (B6; $_{129}S_4$-$F8^{tm1Kaz}$/J) with targeted destruction of exon 16 of the FVIII gene were previously described and kindly provided by H. H. Kazazian Jr (University of Pennsylvania, Philadelphia, PA, USA) [18]. The experimental protocol was approved by the institutional Animal Care and Concern Committee of Jichi Medical University.

Intrathymic injection under the real-time high-resolution imaging system

Hemophilia A mice, 1–3 days old, were anesthetized by inhalation with 2.5% isoflurane in the anesthesia unit (Univentor, ZTN 08, Malta), and were imaged with a 30–50-MHz mechanical sector transducer with 50-μm axial and 115-μm lateral resolution (Vevo 770; Visualsonic Inc., Toronto, Canada). Two-dimensional real-time imaging of the thymus was accomplished with a 12 × 12-mm field of view and an optimal depth of 12.5 mm. When a cross-section with the thymus was located, a glass microcapillary needle (Becton Dickinson, San Jose, CA, USA) was placed at the parasternal area on the chest in the ultrasound imaging plane. Under real-time image guidance, the thymus was punctured with the needle, and 0.05 U g^{-1} body weight (BW) of highly purified, albumin-free preparations of recombinant FVIII (Kogenate FS; Bayer Healthcare, Leverkusen, Germany) or 0.005 U g^{-1} BW of human albumin (Sigma-Aldrich, St Louis, MO, USA) was injected precisely using a microinjector remote control system (Fig. 1A,B). Mice were then stimulated with intravenous FVIII (0.05 U g^{-1} BW) every 2 weeks, from 10 to 18 weeks of age. Blood samples were obtained 2 weeks after each of the injections from the jugular vein, and were added at a 9 : 1 (v/v) ratio to 0.38% sodium citrate; plasma was then separated by centrifugation. The plasma samples were subsequently stored at − 80 °C until further analysis.

Assay for FVIII inhibitors

FVIII inhibitor levels were measured according to the Bethesda methods. In brief, mouse plasma (50 μL) was incubated with 50 μL of normal pooled human plasma at 37 °C for 2 h. Residual human FVIII activity was measured in a one-stage assay using 50 μL of FVIII-deficient human plasma (Kokusai-Shiyaku, Kobe, Japan) and a 50-μL sample from the previous incubation. Samples were mixed with 100 μL of phospholipid activator, incubated at 37 °C for 3 min, and then mixed with 100 μL of 20 mmol L^{-1} $CaCl_2$. Clotting times were measured with a coagulometer (CA-500; Sysmex, Kobe, Japan). Coagutrol N



Fig. 1. Intrathymic injection of FVIII antigen using a high-resolution ultrasound system. Under real-time imaging of the thymus (A), a glass microcapillary needle was placed at the parasternal area and used to puncture the thymus (B). (C) The thymic sections were analyzed with hematoxylin and eosin staining 5 days after without (left panel) or with (right panel) thymic injection of FVIII in hemophilia A mice.

© 2009 International Society on Thrombosis and Haemostasis

(Kokusai-Shiyaku) was diluted with Owren's Veronal Buffer to produce a standard curve of FVIII activity. The measurements were made in the linear portion of the response range.

Anti-FVIII IgG measurements

Anti-FVIII IgG concentrations were determined by an enzyme-linked immunosorbent assay (ELISA) in microtiter wells (Nunc, Roskilde, Denmark) coated with 1 μg mL^{-1} recombinant human full-length FVIII (Kogenate FS). After blocking with 5% bovine serum albumin (BSA) in phosphate-buffered saline (PBS), serial dilutions of murine plasma were added at 4 °C for 16 h. Each well was washed with 0.5% BSA in PBS containing 0.05% Tween-20. Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Cappel, Aurora, OH, USA) was added at 37 °C for 1 h. ABTS Microwell substrate (KPL, Gaithersburg, MD, USA) was added, and the absorbance at 405 nm was read. Anti-FVIII antibody concentrations were estimated from the linear portion of a standard curve obtained using anti-human FVIII monoclonal antibodies (kindly provided by The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan), which bind to FVIII.

Determination of IgG subclass of anti-FVIII antibodies

Microtiter wells were coated with 1 μg mL^{-1} recombinant human FVIII in PBS for 16 h at 4 °C. After blocking with 5% BSA in PBS, serial dilutions of murine plasma were added for 2 h at 37 °C. The wells were washed with 0.5% BSA in PBS containing 0.05% Tween-20. The IgG subtypes of anti-FVIII antibodies bound to immobilized human FVIII were determined by incubation with isotype-specific rabbit anti-mouse IgGs (Mouse Typer; BioRad, Hercules, CA, USA) for 1 h at 37 °C. After being washed with 0.5% BSA in PBS containing 0.05% Tween-20, the wells were incubated with goat anti-rabbit HRP conjugate for 1 h at 37 °C. Substrate development was performed for 15 min at 25 °C, using ABTS Microwell substrate as described above.

Tetanus immunization of FVIII-deficient mice

Mice were injected intraperitoneally with 1 Limit of flocculation of tetanus toxoid (TT) vaccine (Takeda Chemical Industries, Tokyo, Japan). Plasma samples were obtained after 3 weeks, and anti-TT antibody titers were determined by ELISA as previously described. In brief, microtiter plates were coated with 5 μg mL^{-1} formaldehyde-inactivated tetanus toxin, *Clostridium tetanii* (Calbiochem, Darmstadt, Germany), for 16 h at 4 °C. After washing and blocking with Tris-buffered saline containing 5% BSA, mouse plasma samples were added to the wells and incubated for 2 h at 37 °C. After washing with 0.5% BSA in PBS containing 0.05% Tween-20, 100 μL of HRP-conjugated goat anti-mouse IgG was added for 1 h at 37 °C. Then, the peroxidase substrate was added and the absorbance at 405 nm was measured.

Cell preparation

Mice $CD4^+$ T cells were prepared by depletion of non-$CD4^+$ T cells with the autoMACS cell sorting system (Miltenyi Biotech GmbH, Bergish Gladbach, Germany), according to the manufacturer's instructions. $CD4^+CD25^+$ T cells were isolated by $CD25^+$ positive selection from $CD4^+$ T cells with magnetic cell sorting, using a CD4CD25 Isolation Kit (Miltenyi Biotech). The purity of sorted $CD4^+CD25^+$ T cells was confirmed to be more than 85% by flow cytometric analysis. Antigen-presenting cells were prepared from mice splenocytes by depletion of T cells using the magnetic sorting system with anti-CD90 (Thy1.2)-conjugated microbeads (Miltenyi Biotech), followed by irradiation with a single dose of 20 Gy (Gamma Cell; Norton International, ON, Canada), to prevent nonspecific proliferative responses during the *in vitro* FVIII stimulation assay.

Flow cytometric analysis

Cells from teased organs were labeled in PBS containing 1% BSA and 2 mmol L^{-1} EDTA at 4 °C for 30 min in the dark under continuous agitation. The following antibodies were used for phenotypic analysis: allophycocyanin-labeled anti-CD25 IgG (PC61.5; eBioscience, San Diego, CA, USA), fluorescein isothiocyanate-conjugated anti-CD4 IgG, phycoerythrin (PE)-labeled anti-CD45 IgG (30-F11; BD Pharmigen, Franklin Lakes, NJ, USA), and forkhead family transcription factor (Foxp3)–PE IgG (eBio7979; eBioscience), used according to the manufacturer's instructions. Isotype-matched irrelevant antibodies (BD Pharmigen) were used as controls. At least three events were analyzed on a FACS Aria (Becton Dickinson).

Proliferation assay with [^{3}H]thymidine incorporation

To measure T-cell proliferation, 1×10^5 cells per well were cultured with 0–3 nmol L^{-1} human FVIII at 37 °C for 72 h in complete RPMI-1640 (Gibco BRL, Rockville, MD, USA). [^{3}H]Thymidine (Amershan Bioscience, Uppsala, Sweden) was added (0.037 MBq per well) at 37 °C for 18 h. The cells were harvested, and [^{3}H]thymidine incorporation was determined by scintillation counting (Top count; Packard, Meriden, CT, USA).

Cytokine assays

Splenocytes were incubated in 24-well plates at 1.0×10^6 cells per well in the absence or presence of 3 nmol L^{-1} human recombinant full-length FVIII (Kogenate FS) at 37 °C in 5% CO_2. Production of the cytokines interleukin (IL-2), IL-4, IL-12 and IFN-γ by $CD4^+$ T cells derived from each mouse was analyzed at 72 h with the ELISA kits (Biotrak ELISA System; Amersham Biosciences, Piscataway, NJ, USA), according to the manufacturer's instructions. In addition, levels of IL-10 were measured at 96 h by the ELISA system (Biotrak ELISA System).

© 2009 International Society on Thrombosis and Haemostasis

Adoptive transfer of $CD4^+CD25^+$ regulatory T cells into syngeneic hemophilia A mice

Single-cell suspensions were prepared and pooled from the spleens of hemophilia A mice without intrathymic administration of FVIII (non-IT mice) or those with intrathymic administration of FVIII (FVIII-IT mice). The pooled cells were purified to obtain $CD4^+CD25^+$ T-cell populations as described above. A total of 0.5×10^6 $CD4^+CD25^+$ T cells per body in 100 μL of PBS was injected into syngeneic naïve hemophilia A mice via the jugular vein. Mice were challenged with repeated intravenous stimulation by 0.05 U g^{-1} BW FVIII every 2 weeks, and inhibitory antibody titers were followed over time.

Statistical analysis

Two-tailed unpaired t-tests with 95% confidence intervals were performed using SPSS software (SPSS, Chicago, IL, USA). Mean values were considered to be statistically significant if the P-values were below 0.05.

Results

Effect of intrathymic administration of FVIII on anti-FVIII inhibitory antibody formation in hemophilia A mice

We performed histologic analysis of hemophilia A mice 1 day after direct thymic injection of human recombinant FVIII. We analyzed thymus sections 5 days after thymic injection with hematoxylin and eosin staining, and confirmed that there was no bleeding or histologic change in thymic structure, similar to what was seen with untreated mice (Fig. 1C). Then, we studied the impact of intrathymic injection of FVIII on the immune response in hemophilia A mice. For this, we administrated FVIII or albumin as control antigen into the thymus of naïve hemophilia A mice, and analyzed anti-FVIII inhibitory antibody formation after repeated intravenous stimulation with FVIII (0.05 U g^{-1} body weight). All non-IT mice developed high titers of anti-FVIII antibodies (n = 22, 122.5 ± 27.6 BU mL^{-1}; Fig. 2B), confirming that human FVIII is highly immunogenic in hemophilic mice [3,19]. In addition, mice that had been given intrathymic injections of human albumin (Alb-IT mice) showed high titers of antibody against FVIII (n = 10, 129.0 ± 40.6 BU mL^{-1}, Fig. 2C). By contrast, FVIII-IT mice had undetectable or low titers of anti-FVIII antibodies (n = 18, 9.4 ± 2.3 BU mL^{-1}; Fig. 2D). Moreover, FVIII-IT mice did not develop of high titers of anti-FVIII antibodies even after the boosted immune challenges with a combination of FVIII and Freund's adjuvant (20.1 ± 8.1 BU mL^{-1}, n = 5; Fig. 2E). As shown in Fig. 2F, mice treated on day 7, day 14 and day 70 developed high titers of anti-FVIII antibodies after the fifth intravenous stimulation with FVIII: 118.3 ± 34.9 BU mL^{-1} (n = 15), 113.9 ± 31.5 BU mL^{-1} (n = 10), and 120.5 ± 37.6 BU mL^{-1} (n = 16), respectively. Several researchers have demonstrated that induction of antigen-specific tolerance by intrathymic inoculation of soluble antigens is dose-dependent, and that an optimal dose of soluble antigen is required to induce antigen-specific unresponsiveness [20,21]. We injected FVIII into the thymus of neonatal hemophilia A mice at variable doses (0.005–0.5 U g^{-1} BW), and followed this with repeated intravenous stimulation with FVIII at 10, 12, 14, 16 and 18 weeks. As shown in Fig. 2G, intrathymic administration of 0.005, 0.05 and 0.5 U g^{-1} BW resulted in lower titers of anti-FVIII inhibitory antibodies (24.5 ± 4.4, 9.4 ± 2.3, and 18.9 ± 4.8 BU mL^{-1}, respectively) than those seen without thymic treatment. Interestingly, mice injected intrathymically with 0.005 U g^{-1} BW of FVIII developed significantly higher titers of anti-FVIII antibodies than those injected with 0.05 U g^{-1} BW of FVIII (P = 0.036), suggesting that there is some dose-dependency in the ability to induce immune tolerance. Taken together, these findings show that the intrathymic injection of FVIII antigen within 3 days after birth minimizes neutralizing antibody formation in FVIII-deficient mice. To determine whether the suppression of antibody against FVIII was specific, FVIII-IT mice and non-IT mice were immunized intraperitoneally with TT vaccine 2 weeks after the final challenge with FVIII. As shown in Fig. 2H, FVIII-IT mice were able to mount a T-cell-dependent immune response to a different antigen, and the antibody response was similar to that in non-IT mice. These results indicated that the immune suppression observed in our mouse model was FVIII-specific.

Fig. 2. Effect of intrathymic administration of FVIII on anti-FVIII inhibitory antibody formation in hemophilia A mice. Normal B6 control mice [(A), n = 5], and hemophilia A mice without thymic treatment [(B), n = 22], or with thymic injection of human albumin [(C), n = 10] or human FVIII [(D), n = 18] within 3 days after birth, were injected intravenously with human FVIII (0.05 U g^{-1} body weight) at 10, 12, 14, 16 and 18 weeks. The anti-FVIII inhibitor titer was determined by Bethesda assay. (E) FVIII-deficient mice with prior intrathymic injection of FVIII were repeatedly stimulated with FVIII and Freund's adjuvant every 2 weeks, and anti-FVIII inhibitor titers were measured. (F) The initial intrathymic injection of FVIII was given within 3 days (n = 22), 7 days (n = 15), 14 days (n = 10) or 70 days (n = 18) after birth. Each mouse was then given repeated intravenous injections at 10, 12, 14, 16 and 18 weeks. The mice were bled on day 4 after the fifth treatment, and anti-FVIII inhibitor titers were measured. Bars show means. $**P < 0.03$ (G) Zero unit per gram body weight (saline control, n = 18), 0.005 U g^{-1} body weight (saline control, n = 10), 0.05 U g^{-1} body weight (saline control, n = 22) or 0.5 U g^{-1} body weight (saline control, n = 11) of FVIII were injected into the thymus within 3 days after birth, and the mice were then treated with 0.05 U g^{-1} body weight of FVIII at 10, 12, 14, 16 and 18 weeks. The mice were bled on day 4 after the fifth treatment, and anti-FVIII inhibitor titers were measured by Bethesda assay. Bars show means. $*P < 0.05$, $**P < 0.03$ (H) Hemophilia A mice without (n = 14, open bar) or with (n = 15, closed bar) thymic administration of FVIII were given five doses of intravenous FVIII (0.05 U g^{-1} body weight) every 2 weeks. Each mouse was injected intraperitoneally with one Limit of flocculation (Lf) unit per body of tetanus toxoid vaccine 2 weeks after the last challenge with FVIII. Plasma samples were obtained 3 weeks after the tetanus toxoid injection. Anti-tetanus toxoid antibody titers were measured by enzyme-linked immunosorbent assay as described in Materials and methods. Data are shown as the means ± standard deviations.

© 2009 International Society on Thrombosis and Haemostasis



Effect of intrathymic administration of FVIII on anti-FVIII IgG formation in hemophilia A mice

We treated hemophilia A mice with repeated injections of human FVIII, and measured anti-FVIII IgG titers after the fifth injection at 16 weeks. IgG antibodies against FVIII were significantly inhibited in FVIII-IT mice as compared with non-IT mice (14.9 ± 11.2 μg mL^{-1} vs. 665.16 ± 225.4 μg mL^{-1}, $P = 0.0038$) (Fig. 3A). As these mice are on a B6 background, we used C57BL/6J mice as normal controls for experiments on the development of anti-FVIII IgG. The B6 control mice developed high titers of anti-FVIII inhibitory antibodies (101.6 ± 46.4 BU mL^{-1}; Fig. 2A). Levels of anti-FVIII IgG of FVIII-stimulated B6 control mice (409.9 ± 84.8 μg mL^{-1})

© 2009 International Society on Thrombosis and Haemostasis



Fig. 3. Effect of intrathymic administration of FVIII on anti-FVIII IgG formation in hemophilia A mice. Normal B6 control mice (B6 control mice, $n = 5$), naïve FVIII-deficient mice (naïve mice, $n = 5$), FVIII-deficient mice without thymic treatment (non-IT mice, $n = 5$) and mice with prior thymic injection of human albumin (Albumin-IT mice, $n = 5$) or human FVIII (FVIII-IT mice, $n = 5$) were injected intravenously with human FVIII every 2 weeks. Each of the mice was bled on day 4 after the fifth stimulation, and total anti-human FVIII IgGs (A) and their titers of IgG subclasses (B) were measured by enzyme-linked immunosorbent assay as described in Materials and methods. The values [(A), μg mL^{-1}; (B), AU] represent the means ± standard deviations. $*P < 0.05$; $**P < 0.03$.

were significantly higher than those of FVIII-deficient naïve (5.0 ± 5.6 μg mL^{-1}, background values) or FVIII-IT mice. In addition, Alb-IT mice also produced significant amounts of anti-FVIII IgG antibodies (616.4 ± 207.9 μg mL^{-1}). All IgG isotypes of anti-FVIII antibodies in B6 control, Alb-IT and non-IT mice significantly increased as compared with those in FVIII-IT mice (Fig. 3B). These results suggest that intrathymic injection of FVIII efficiently suppressed the formation of antibodies against FVIII in hemophilia A mice.

The anti-FVIII specific CD4⁺ T-cell proliferative response is blocked by intrathymic administration of FVIII

To evaluate whether intrathymic administration of FVIII had direct suppressive effect on FVIII-specific $CD4^+$ T cells, we analyzed the $CD4^+$ T-cell proliferative response to *in vitro* FVIII stimulation in the presence or absence of non-IT mouse-derived antigen-presenting cells (Fig. 4A). As shown in Fig. 4B, $CD4^+$ T cells isolated from B6 control, naïve, non-IT, Alb-IT or FVIII-IT mice did not proliferate at any concentration of FVIII when they were cultured without antigen-presenting cells. Moreover, the antigen-presenting cells alone did not respond to the stimulation with FVIII. The $CD4^+$ T cells of B6 control, non-IT and Alb-IT mice showed dose-dependent proliferation in response to FVIII when they were cocultured with the antigen-presenting cells (Fig. 4C). By contrast, the $CD4^+$ T cells isolated from FVIII-IT mice did not show any proliferative response to FVIII, even if they were cocultured with antigen-presenting cells, indicating that the intrathymic administration of FVIII could be important for the prevention of an immune response to FVIII.

Cytokine responses are suppressed by intrathymic administration of FVIII

The $CD4^+$ T cells from B6 control (Fig. 5A), non-IT (Fig. 5C) and Alb-IT (Fig. 5D) mice produced significant amounts of IL-2, IL-12 and IFN-γ in response to FVIII stimulation. In contrast, the levels of IL-4 and IL-10 in

© 2009 International Society on Thrombosis and Haemostasis



Fig. 4. The anti-FVIII specific T-cell proliferative response is blocked by intrathymic administration of FVIII. (A) B6 control mice, mice without intrathymic administration of FVIII (non-IT mice), mice that had been given intrathymic injections of human albumin (Alb-IT mice) and mice that had been given intrathymic injections of FVIII (FVIII-IT) mice were intravenously injected with human FVIII every 2 weeks. The $CD4^+$ T cells were isolated from each of the mice, as well as from naïve FVIII-deficient mice, by depletion of CD8a, CD11b, CD45R, CD49b and Ter119 cells with a cell sorting system. The antigen-presenting cells were isolated from non-IT mice after repeated intravenous stimulation with FVIII with depletion of CD90 cells, followed by 20 Gy of irradiation. Each group of $CD4^+$ T cells was stimulated with FVIII in the absence or presence of the antigen-presenting cells. (B) The proliferation of $CD4^+$ T cells from B6 control mice (closed triangles, $n = 5$), naïve mice (open squares, $n = 5$), non-IT mice (open circles, $n = 7$), Alb-IT mice (closed squares, $n = 5$) and FVIII-IT mice (closed circles, $n = 7$) was analyzed under *in vitro* stimulation with FVIII (0–3 nmol L^{-1}) in the absence of antigen-presenting cells, as described in Materials and methods. The proliferation of antigen-presenting cells alone was also analyzed (open triangles, $n = 5$). (C) The proliferation of $CD4^+$ T cells from B6 control mice (closed triangles, $n = 5$), naïve mice (open squares, $n = 5$), non-IT mice (open circles, $n = 7$), Alb-IT mice (closed squares, $n = 5$), and FVIII-IT mice (closed circles, $n = 7$) was analyzed under *in vitro* stimulation with FVIII (0–3 nmol L^{-1}) in the presence of the non-IT mouse-derived antigen-presenting cells. Data are shown as the means ± standard deviations. $*P < 0.05$, $**P < 0.03$, when compared with the proliferation in the absence of FVIII.

these mice did not change even after addition of FVIII. FVIII-IT mice spontaneously produced higher amounts of IL-4 (71.2 ± 40.5 pg mL^{-1}; Fig. 5E) than non-IT mice (14.7 ± 6.8 pg mL^{-1}, $P = 0.016$; Fig. 5C) or Alb-IT mice (26.6 ± 2.9 pg mL^{-1}, $P = 0.035$; Fig. 5D). IL-4 has been shown to be the dominant cytokine required for the development of a Th2 phenotype from naïve $CD4^+$ T cells [22]. The population of $CD4^+$ T cells or antigen-presenting cells may be heterogeneous and contain a subpopulation of cells (such as Th3 cells) capable of producing IL-4 in our system [23]. Alternatively, IL-4, as a regulatory cytokine, might tend to suppress Th1 responses and enhance

© 2009 International Society on Thrombosis and Haemostasis

regulatory T-cell function in FVIII-IT mice [24]. In addition, the FVIII-IT-mouse-derived $CD4^+$ T cells did not increase their production of the cytokines IL-2, IL-12, IFN-γ and IL-10 (Fig. 5E). These results suggest that the FVIII-specific Th1 cytokine response is suppressed by intrathymic administration of FVIII.

Intrathymic administration of FVIII induces antigen-specific regulatory T cells

To evaluate the role of FVIII-specific regulatory T cells in the induction of thymic tolerance, we analyzed $CD4^+CD25^+$ T cells and $FoxP3^+$ cells after *in vitro* stimulation with FVIII



Fig. 5. The Th1 cytokine response is suppressed by intrathymic administration of FVIII. The $CD4^+$ T cells isolated from normal B6 control mice [(A), $n = 5$], FVIII-deficient mice without intrathymic administration of FVIII (non-IT mice) [(C), $n = 6$], mice that had been given intrathymic injections of human albumin [(D), $n = 5$] and mice that had been given intrathymic injections of FVIII [(E), $n = 8$] after repeated intravenous stimulation with FVIII were mixed with the antigen-presenting cells derived from non-IT mice with FVIII stimulation. The $CD4^+$ T cells from FVIII-deficient naïve mice were also examined with the antigen-presenting cells [(B), $n = 5$]. Each group of cells was cultured in the absence (open bars) or presence of 3 nmol L^{-1} FVIII (closed bars), and its cytokine production [interleukin (IL)-2, IL-4, IL-10, IL-12, and interferon-γ (IFN-γ)] were analyzed by enzyme-linked immunosorbent assay as described in Materials and methods. The values (pg mL^{-1}) represent the means ± standard deviations. $*P < 0.05$; $**P < 0.03$.

© 2009 International Society on Thrombosis and Haemostasis



Fig. 6. Injection of FVIII into the thymus increases the numbers of FVIII-specific $CD25^+FoxP3^+$ cells. (A) The lymph node and spleen-derived $CD4^+$ T cells of normal B6 control mice, FVIII-deficient mice without intrathymic administration of FVIII (non-IT mice), mice that had been given intrathymic injections of human albumin (albumin-IT mice) or mice that had been given intrathymic injections of FVIII (FVIII-IT mice) with repeated intravenous FVIII stimulation were cultured with antigen-presenting cells from FVIII-stimulated non-IT mice in the presence of 3 nmol L^{-1} FVIII for 72 h. The $CD4^+$ T cells of FVIII-deficient naïve mice were also cultured with antigen-presenting cells and FVIII antigen. The percentage of $CD25^+FoxP3^+$ cells among $CD4^+$ T cells was analyzed by flow cytometry as described in Materials and methods. (B) The frequencies of FVIII-specific-$CD25^+FoxP3^+$ cells among $CD4^+$ T cells isolated from the lymph nodes and spleens of B6 control mice (n = 6), naïve mice (n = 6), non-IT mice (n = 6), albumin-IT mice (n = 6) or FVIII-IT mice (n = 6) were analyzed. $^{**}P < 0.03$ as compared with those of other groups. (C) The standard regulatory T-cell inhibition assay. Under stimulation by anti-mouse CD3 antibodies (BD Biosciences), the proliferation of naïve normal B6-derived $CD4^+CD25^-$ T cells was analyzed in the presence of $CD4^+CD25^+$ T cells from B6 control mice (closed triangles, n = 5), FVIII-deficient naïve mice (open squares, n = 5), non-IT mice (open circles, n = 5), albumin-IT mice (closed squares, n = 5), or FVIII-IT mice (closed circles, n = 5), at a variety of ratios. PE, phycoerythrin.

© 2009 International Society on Thrombosis and Haemostasis